prof. dr. Fritz Offner
- ORCID iD
-
0000-0003-4690-3603
Show
Sort by
-
- Journal Article
- A1
- open access
CCR1 inhibition sensitizes multiple myeloma cells to glucocorticoid therapy
-
Real-world evaluation of treatments and outcomes of follicular lymphoma in Belgium
-
- Journal Article
- A1
- open access
Glofitamab in relapsed/refractory mantle cell lymphoma : results from a phase I/II study
-
- Journal Article
- A1
- open access
Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma : ELARA trial update
-
Glofitamab monotherapy in patients with heavily pretreated relapsed/refractory (R/R) mantle cell lymphoma (MCL) : updated analysis from a phase I/II study
-
Epcoritamab with rituximab plus lenalidomide (R2) in previously untreated (1L) follicular lymphoma (FL) and epcoritamab maintenance in FL: EPCORE NHL-2 arms 6 and 7
-
Epcoritamab plus R-DHAX/C in transplant-eligible patients (pts) with high-risk relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL)
-
Glofitamab monotherapy retreatment in patients with heavily pre-treated relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) : results from a phase I/II study
-
Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma : long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial
-
Clinical outcomes of patients with relapsed/refractory follicular lymphoma (R/R FL) treated with tisagenlecleucel : phase 2 ELARA 3-year follow-up
(2024) CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. In Clinical Lymphoma Myeloma & Leukemia 24(Supplement 1). p.S495-S496